Amgen Inc. $AMGN Shares Sold by M&G PLC

M&G PLC cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 14.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 248,645 shares of the medical research company’s stock after selling 41,174 shares during the quarter. M&G PLC’s holdings in Amgen were worth $104,928,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of AMGN. Rational Advisors Inc. boosted its position in shares of Amgen by 13.7% in the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after buying an additional 24 shares in the last quarter. Beacon Financial Advisory LLC grew its stake in Amgen by 2.0% in the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after acquiring an additional 25 shares during the last quarter. James T. Borello RIA increased its holdings in Amgen by 13.6% during the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock valued at $88,000 after acquiring an additional 25 shares in the last quarter. Sweeney & Michel LLC increased its holdings in Amgen by 0.5% during the 3rd quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock valued at $2,162,000 after acquiring an additional 25 shares in the last quarter. Finally, Legacy Financial Advisors Inc. increased its holdings in Amgen by 0.8% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after acquiring an additional 26 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Amgen stock opened at $465.23 on Tuesday. The firm has a market capitalization of $251.52 billion, a P/E ratio of 26.99, a PEG ratio of 3.47 and a beta of 0.43. The stock has a fifty day moving average price of $423.08 and a 200 day moving average price of $378.80. Amgen Inc. has a 52 week low of $312.39 and a 52 week high of $483.99. The company has a current ratio of 1.48, a quick ratio of 1.13 and a debt-to-equity ratio of 3.60.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The firm had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. During the same period last year, the company earned $5.64 EPS. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. Equities research analysts anticipate that Amgen Inc. will post 23.33 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is 58.47%.

Analysts Set New Price Targets

Several research firms have recently commented on AMGN. Mizuho increased their price target on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. William Blair restated an “outperform” rating on shares of Amgen in a research report on Wednesday, November 4th. Morgan Stanley upped their target price on Amgen from $359.00 to $410.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 4th. Leerink Partners boosted their price target on Amgen from $395.00 to $464.00 and gave the stock a “market perform” rating in a report on Thursday, November 5th. Finally, Citigroup boosted their target price on shares of Amgen from $405.00 to $465.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average price target of $422.76.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
• Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
• Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen’s new drug could mean fewer shots for obesity patients
• Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
• Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.